Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy

José L. Blanco; Julio S.G. Montaner; Vincent C. Marconi; Maria M. Santoro; Ariel E. Campos-Loza; Robert W. Shafer; Michael D. Miller; Roger Paredes; Richard Harrigan; Mihn L. Nguyen; Carlo F. Perno; Lucero A. Gonzalez-Hernandez; José M. Gatell

doi:10.1097/QAD.0000000000000424

Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy

José L. Blanco, Julio S.G. Montaner, Vincent C. Marconi, Maria M. Santoro, Ariel E. Campos-Loza, Robert W. Shafer, Michael D. Miller, Roger Paredes, Richard Harrigan, Mihn L. Nguyen, Carlo F. Perno, Lucero A. Gonzalez-Hernandez, José M. Gatell

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

29 Cites (Scopus)

Resum

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. Background: Fixed-dose combination antiretroviral therapy administered as a singletablet regimen (STR) may improve virologic suppression rates. The effect of STRs on development of resistance when virologic failure occurs on STRs is not known.

Idioma original	Anglès
Pàgines (de-a)	2531-2539
Revista	AIDS
Volum	28
Número	17
DOIs	https://doi.org/10.1097/QAD.0000000000000424
Estat de la publicació	Publicada - 1 de gen. 2014

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1097/QAD.0000000000000424

Altres arxius i enllaços

https://www.scopus.com/pages/publications/84927774765

Com citar-ho

Blanco, J. L., Montaner, J. S. G., Marconi, V. C., Santoro, M. M., Campos-Loza, A. E., Shafer, R. W., Miller, M. D., Paredes, R., Harrigan, R., Nguyen, M. L., Perno, C. F., Gonzalez-Hernandez, L. A., & Gatell, J. M. (2014). Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy. AIDS, 28(17), 2531-2539. https://doi.org/10.1097/QAD.0000000000000424

@article{8bc6043580e54a6291d14798b0f41d8e,

title = "Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy",

abstract = "{\textcopyright} 2014 Wolters Kluwer Health | Lippincott Williams \& Wilkins. Background: Fixed-dose combination antiretroviral therapy administered as a singletablet regimen (STR) may improve virologic suppression rates. The effect of STRs on development of resistance when virologic failure occurs on STRs is not known.",

keywords = "Antiretroviral treatment, Atripla, HIV-1 resistance, Single-tablet regimen",

author = "Blanco, \{Jos{\'e} L.\} and Montaner, \{Julio S.G.\} and Marconi, \{Vincent C.\} and Santoro, \{Maria M.\} and Campos-Loza, \{Ariel E.\} and Shafer, \{Robert W.\} and Miller, \{Michael D.\} and Roger Paredes and Richard Harrigan and Nguyen, \{Mihn L.\} and Perno, \{Carlo F.\} and Gonzalez-Hernandez, \{Lucero A.\} and Gatell, \{Jos{\'e} M.\}",

year = "2014",

month = jan,

day = "1",

doi = "10.1097/QAD.0000000000000424",

language = "English",

volume = "28",

pages = "2531--2539",

number = "17",

}

Blanco, JL, Montaner, JSG, Marconi, VC, Santoro, MM, Campos-Loza, AE, Shafer, RW, Miller, MD, Paredes, R, Harrigan, R, Nguyen, ML, Perno, CF, Gonzalez-Hernandez, LA & Gatell, JM 2014, 'Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy', AIDS, vol. 28, núm. 17, pàg. 2531-2539. https://doi.org/10.1097/QAD.0000000000000424

Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy. / Blanco, José L.; Montaner, Julio S.G.; Marconi, Vincent C. et al.
In: AIDS, Vol. 28, Núm. 17, 01.01.2014, pàg. 2531-2539.

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy

AU - Blanco, José L.

AU - Montaner, Julio S.G.

AU - Marconi, Vincent C.

AU - Santoro, Maria M.

AU - Campos-Loza, Ariel E.

AU - Shafer, Robert W.

AU - Miller, Michael D.

AU - Paredes, Roger

AU - Harrigan, Richard

AU - Nguyen, Mihn L.

AU - Perno, Carlo F.

AU - Gonzalez-Hernandez, Lucero A.

AU - Gatell, José M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. Background: Fixed-dose combination antiretroviral therapy administered as a singletablet regimen (STR) may improve virologic suppression rates. The effect of STRs on development of resistance when virologic failure occurs on STRs is not known.

AB - © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. Background: Fixed-dose combination antiretroviral therapy administered as a singletablet regimen (STR) may improve virologic suppression rates. The effect of STRs on development of resistance when virologic failure occurs on STRs is not known.

KW - Antiretroviral treatment

KW - Atripla

KW - HIV-1 resistance

KW - Single-tablet regimen

UR - https://www.scopus.com/pages/publications/84927774765

U2 - 10.1097/QAD.0000000000000424

DO - 10.1097/QAD.0000000000000424

M3 - Article

SN - 0269-9370

VL - 28

SP - 2531

EP - 2539

JO - AIDS

JF - AIDS

IS - 17

ER -

Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho